ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

ANIPยทNASDAQ

$75.23

-1.9%
HealthcareDrug Manufacturers - Specialty & Generic

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

At a Glance

Live Snapshot
Market Cap$1.71B
EPS3.5000
P/E Ratio21.49
Earnings Date08/14/2026
3Y-694.0%
5Y+1113.0%
10Y+574.0%
3Y+118.0%
5Y-50.0%
10Y-78.0%
3Y+94.0%
5Y+591.0%
10Y+1264.0%
ANIP

ANI Pharmaceuticals, Inc. Cash Conversion Engine

ANIP ยท NASDAQ
Net Income78.34M
Depreciation & Amortization91.42M
Stock-Based Compensation37.93M
Change in Working Capital-7.12M
Others-29.57M
Capital Expenditures-13.84M
Free Cash Flow171.39M

Cash Flow Quality Analysis

FCF Conversion Rate

218.8%

Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.

CapEx Intensity

7.5%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+264.2%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$7.12M

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.

ANI Pharmaceuticals, Inc. Cash Flow Statement

ANIP โ€ข NASDAQ

ANI Pharmaceuticals, Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
OPERATING ACTIVITIES
78.3M
-18.5M
18.8M
-47.9M
-42.6M
-22.5M
6.1M
15.5M
-1.1M
3.9M
15.4M
28.7M
301K
-27.7M
-51.6M
-46.2M
-47.5M
-17.4M
-7.6M
2.8M
91.4M
67.7M
59.8M
59.7M
47.3M
44.6M
44.6M
33.7M
27.9M
22.3M
6.9M
3.9M
1.1M
258.9K
148.2K
168K
137.3K
43.1K
89.8K
117.8K
14.2M
-21.9M
-11.7M
-15.3M
-16.8M
-13.2M
-9.1M
-5.2M
3.6M
-8.9M
-1.9M
-14.5M
-195K
1M
52M
290.6K
0.0
0.0
0.0
0.0
37.9M
29.3M
20.7M
14.6M
10.5M
12.9M
9.2M
6.8M
6.1M
6.1M
3.9M
3.4M
4.5M
725.6K
1.2M
992.8K
1.3M
1.1M
0.0
0.0
-29.6M
18.6M
6.6M
9M
5M
6.1M
9.4M
10.3M
8.6M
14M
6.9M
559K
217K
4.3M
-51.4M
1.9M
29.3M
104.3K
625.9K
1.1M
(17.7M)
(19.1M)
(1.2M)
(288K)
(10.4M)
(5M)
(10M)
(6.4M)
(17.8M)
(9.5M)
(13.3M)
-147K
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-7.1M
-11.2M
24.9M
-51.3M
-84K
-12.6M
-14.6M
6M
-5.7M
-9.9M
-13.9M
-115K
-11.4M
-3.9M
1.8M
2.8M
-1.6M
639.4K
7.6M
-9M
185.2M
64M
119M
-31.2M
3.3M
15.3M
45.6M
67.1M
39.4M
27.5M
17.3M
22M
-5.5M
-25.3M
-47.9M
-40.1M
-18.4M
-15.5M
740K
-5M
INVESTING ACTIVITIES
-34.3M
-16.2M
-8.9M
-8.9M
-2.6M
-6.1M
-27.5M
-10.9M
-108M
-149.1M
-32.7M
-35.8M
-191K
-611.2K
-719.9K
-63.4K
-165.7K
-651.1K
-29.4K
-39.3K
(0.0)
-401.3M
(0.0)
-33K
-84.5M
(0.0)
(0.0)
-16.5M
(0.0)
(0.0)
(0.0)
(0.0)
(18.2M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-5M
(0.0)
(0.0)
(0.0)
-8K
(0.0)
(0.0)
(0.0)
(0.0)
-11.2M
-8M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
3M
12M
981.0
13M
0.0
12.8M
-9.6M
-6.8M
-18.4M
-62.2M
0.0
-5.2M
-97.6M
-5M
-30.5M
-34.6M
2.3M
0.0
0.0
3.1K
-165.7M
0.0
0.0
0.0
-34.3M
-404.7M
-18.5M
-15.7M
-105.5M
-68.3M
-27.5M
-27.4M
-108M
-154.1M
-32.7M
-35.8M
(20.3M)
-619.1K
-719.9K
-60.4K
(2.9M)
(11.3M)
-11.2M
(5M)
FINANCING ACTIVITIES
1.4M
-11M
75.6M
-2M
68.7M
-1.5M
-1M
-659K
-259K
-122K
-113K
46.7M
-433K
3.3M
68.8M
48.5M
11.4M
319.4K
18.5M
7.4M
-10.2M
345.2M
-3M
-3M
99M
-534K
115.3M
-2.8M
75M
0.0
0.0
138.2M
-4.1M
0.0
-1.2M
0.0
0.0
0.0
0.0
0.0
-1.2M
-1.6M
-1.6M
-1.6M
-190K
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-12.2M
-11M
-5M
-2M
-890K
-1.5M
-1M
-659K
-259K
-2.6M
-113K
(0.0)
-433K
-658.0
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-26K
-67.7M
-3.5M
1.5M
2.1M
618K
-118.8M
-24.3M
-2.4M
323K
1.2M
33.4M
809K
211.1K
56.5K
2K
22.3M
0.0
0.0
0.0
-9.9M
264.9M
67.4M
-5.1M
194.6M
-1.4M
1.3M
-27.8M
72.4M
-729K
1.1M
171.7M
-3.7M
3.5M
67.7M
48.5M
33.7M
319.4K
18.5M
7.4M
CASH FLOW SUMMARY
-233K
-470K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
140.7M
-76.2M
167.9M
-52.1M
92.4M
-54.5M
19.3M
11.9M
3.8M
-127.3M
-14.4M
157.9M
11.1M
-22.4M
19.1M
8.3M
18.1M
-3.9M
8M
7.3M
144.9M
221.1M
53.2M
105.3M
12.9M
67.4M
48M
36.2M
32.4M
154.7M
169M
11.1M
11K
57.2M
38.2M
29.9M
11.8M
15.6M
7.7M
310.6K
285.6M
144.9M
221.1M
53.2M
105.3M
12.9M
67.4M
48M
36.2M
27.4M
154.7M
169M
11.1M
34.8M
57.2M
38.2M
29.9M
11.8M
15.6M
7.7M
171.4M
47.1M
100.4M
-47.7M
-20.3M
-53.1M
18.1M
56.2M
-68.6M
-121.6M
-15.4M
-13.7M
-5.7M
-25.9M
-48.6M
-40.2M
-18.6M
-16.2M
710.6K
-5M

SEC Filings

ANIP - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 21, 2026
May 21, 2026
2026
8-K

8-K 2026

N/A

May 13, 2026
May 13, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 08, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 08, 2026
May 08, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 09, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

April 07, 2026
April 01, 2026
2026
8-K

8-K 2026

N/A

March 03, 2026
March 03, 2026
2026
10-K

10-K 2025 FY

FY

February 27, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 27, 2026
February 27, 2026
2026
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
Showing 1 to 10 of 461 filings